James Investment Research Inc. Sells 12,927 Shares of Pfizer Inc. (NYSE:PFE)

James Investment Research Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 32.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,350 shares of the biopharmaceutical company's stock after selling 12,927 shares during the quarter. James Investment Research Inc.'s holdings in Pfizer were worth $693,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Geode Capital Management LLC increased its holdings in shares of Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares during the period. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth approximately $2,328,986,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Pfizer by 7.7% during the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company's stock worth $1,548,889,000 after acquiring an additional 4,167,222 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of NYSE PFE traded down $0.02 during midday trading on Thursday, reaching $24.59. The company's stock had a trading volume of 47,333,190 shares, compared to its average volume of 41,955,789. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The business's 50 day moving average price is $23.99 and its two-hundred day moving average price is $24.77. The company has a market cap of $139.83 billion, a P/E ratio of 17.82, a P/E/G ratio of 0.90 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.82 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.99%. Pfizer's dividend payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PFE shares. Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Morgan Stanley boosted their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Citigroup lifted their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Redburn Atlantic lowered their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.